Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics (CDTX) delivers innovative solutions for serious infectious diseases through its Cloudbreak® platform, which engineers targeted immunotherapies and anti-infectives. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about CDTX's pipeline candidates, antiviral DFC advancements, and partnership agreements. Our curated collection includes press releases on trial results, FDA interactions, and research collaborations – all critical for evaluating the company's progress in addressing unmet medical needs.
Key updates cover three focus areas: clinical trial phases for antifungal/antiviral therapies, technology licensing deals involving the Cloudbreak® platform, and financial developments impacting R&D priorities. Bookmark this resource to monitor how CDTX's dual approach of direct pathogen targeting and immune system engagement evolves across influenza, oncology, and fungal infection programs.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) reported Q3 2020 financial results, highlighting a net loss of $17.6 million, compared to a net income of $3.0 million in Q3 2019. Revenue totaled $2.4 million for the quarter, significantly down from $19.1 million in the same period last year, largely due to a previous intellectual property licensing deal. Research and development expenses increased to $16.3 million, reflecting higher costs related to rezafungin trials. Cidara continues to advance rezafungin through Phase 3, targeting top-line data by late 2021 amid COVID-19 challenges.
Cidara Therapeutics (Nasdaq: CDTX) presented significant clinical data at IDWeek 2020, highlighting its antifungal candidate, rezafungin, for treating candidemia and invasive candidiasis. Analyses from the completed Phase 2 STRIVE trial demonstrated rezafungin's robust efficacy against multiple Candida species across diverse patient populations. Additionally, data on the Cloudbreak antiviral platform showcased the promising antiviral candidate, CD377, which demonstrated strong protective effects against influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced the presentation of two posters at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting, taking place virtually from October 19-30, 2020. The presentations will feature data on rezafungin, a novel once-weekly echinocandin in pivotal Phase 3 trials for treating serious fungal infections. Key presentations include a pharmacoepidemiologic evaluation and results from the Phase 2 STRIVE clinical trial, showcasing consistent trough concentrations across diverse patient populations.
Cidara Therapeutics (Nasdaq: CDTX) will present findings at IDWeek 2020, focusing on rezafungin, a novel once-weekly echinocandin in Phase 3 trials for serious fungal infections. Key presentations include the STRIVE Phase 2 trial results, showcasing consistent trough concentrations and outcomes based on baseline pathogens and BMI. Additionally, new data on CD377, an antiviral candidate against influenza, will be shared. The presentations will occur from Oct. 21-25, 2020, advancing Cidara's mission to enhance treatment standards for fungal and viral infections.
Cidara Therapeutics (Nasdaq: CDTX) announced the participation of Jeffrey Stein, Ph.D., in four upcoming investor conferences in September 2020. Key events include:
- Citi’s 15th Annual BioPharma Conference: September 9, 2020
- H.C. Wainwright 22nd Annual Global Investment Conference: September 14, 2020, at 4:30 PM ET
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 16, 2020, at 3:20 PM ET
- Maxim Conference: September 17, 2020, at 11:00 AM ET
Webcasts available on the company’s website.
Cidara Therapeutics (Nasdaq: CDTX) reported its financial results for Q2 2020, highlighting significant corporate developments. The company successfully dosed the first patient in its Phase 3 ReSPECT trial for rezafungin, aimed at preventing invasive fungal disease in patients undergoing blood and marrow transplantation. Financially, Cidara had $64.1 million in cash as of June 30, 2020, with increased R&D expenses of $17.6 million due to clinical trial costs. The net loss for Q2 2020 was $18.3 million, compared to $13.5 million in Q2 2019.
Cidara Therapeutics (Nasdaq: CDTX) announced that its CEO, Jeffrey Stein, Ph.D., will join the B. Riley FBR Virtual Summer Series panel on antiviral therapeutics on July 21, 2020, at 1:00 PM ET / 10:00 AM PT. The panel will focus on new approaches in the field of antiviral treatment. Cidara is dedicated to developing long-acting therapeutics to enhance care for patients with serious fungal and viral infections, notably through its lead antifungal candidate, rezafungin, and its Cloudbreak® antiviral platform.
Cidara Therapeutics (Nasdaq: CDTX) announced that CEO Jeffrey Stein will participate in the Cantor Fitzgerald Virtual Symposium on June 30, 2020. The event will focus on innovative approaches to treating infections, including COVID-19, and discuss the importance of stockpiling in the U.S. Cidara is working on groundbreaking therapies to improve care for severe fungal and viral infections, including its lead candidate, rezafungin, and antiviral platform Cloudbreak®. The announcement highlights the company's commitment to addressing critical health challenges.
Cidara Therapeutics (Nasdaq: CDTX) has announced that its CEO, Jeffrey Stein, Ph.D., will present virtually at the Raymond James Human Health Innovations Conference on June 18, 2020, at 3:40 PM ET. The company focuses on developing long-acting therapeutic solutions for serious fungal and viral infections. Notably, Cidara is advancing its lead Phase 3 antifungal candidate, rezafungin, along with antiviral conjugates from its Cloudbreak antiviral platform. Investors can access the live webcast on the company's website.
Cidara Therapeutics has commenced the ReSPECT pivotal Phase 3 clinical trial to evaluate the efficacy and safety of its antifungal candidate, rezafungin, for preventing invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is designed for once-weekly administration, potentially simplifying complex treatment regimens. The trial aims to enroll approximately 462 adults and will compare rezafungin to standard daily antifungal therapies. Successful outcomes may position rezafungin as a new standard of care.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
